Table 1. Review of pharmacokinetic studies of sulfadoxine.

Study	Number of subjects	Samples per subject	Sex	Age [y]	Body weight [kg]	Condition	Analytic method	Sample type	Dose [mg]	Regimen	PK approach	Compartments
Mansor et al. [32]	10	18	males	22–30	51–60	Healthy adults	GC	Plasma	1000	single dose	AUTOAN-NONLIN	2
Obua et al. [33]	83	6	both	2.5	11.9±2.7	Falciparum malaria	HPLC-UV	Whole blood on filter paper	250 or 500	one dose daily for three days	NONMEM	2
Green et al. [34]	33	7	females	15–30	47.2–71.0	Falciparum malaria, pregnancy, HIV positiv	HPLC-UV	Whole blood	1500	single dose	log-linear regression	1
Trenque et al. [35]	89	3	both	0–14	3–59	Congenital toxoplasmosis	HPLC-UV	Plasma	25/kg	two or three times a month	NONMEM	1
Barnes et al. [36]	290	8	both	14	<103	Falciparum malaria	HPLC-MS	Whole blood on filter paper	25/kg, ≤1500	single dose	WinNonlin	1
Edstein et al. [34]	7		both	Adults		Healthy adults		Whole blood	500	single dose
Corvaisier et al. [38]	32	5	both	0.2–2.1	5–13.4	Congenital toxoplasmosis	HPLC-UV	Plasma	25/kg	one dose every 10 days	NPEM	1
Obua et al. [39]	9	14	both			Healthy adults	HPLC-UV	Plasma	1500	single dose	WinNonlin	1